Kiniksa Q2: ARCALYST Revenue Jumps 55%, Guidance Raised to ~$990M; KPL-387 Phase 3 Enrolling
KNSA has more than doubled off its 52-week low of $26.27.
Summary
Kiniksa reported Q2 2026 ARCALYST revenue of $243.6M (+55% YoY), raised full-year guidance to $980–$995M, and advanced KPL-387 into a pivotal Phase 3 trial in recurrent pericarditis.
Key Events · Earnings and Guidance · KNSA
-
ARCALYST Revenue Surges 55%
Q2 2026 ARCALYST net product revenue reached $243.6 million, up from $156.8 million in Q2 2025, driven by increased prescriber adoption and longer treatment durations.
-
Full-Year Guidance Raised
2026 ARCALYST revenue guidance increased to $980–$995 million from prior $930–$945 million, reflecting strong commercial momentum and patient growth.
-
KPL-387 Phase 2 Data Positive
Phase 2 data showed rapid pain and inflammation reduction with once-monthly 300 mg subcutaneous dosing; dose selected for pivotal Phase 3 PASTORALE trial, now enrolling.
-
Strong Balance Sheet
Cash, cash equivalents, and short-term investments totaled $525.9 million as of June 30, 2026, with no debt; company expects to remain cash flow positive.
Analysis · KNSA · Life Sciences
A standout second quarter for Kiniksa was anchored by ARCALYST net product revenue, which surged 55% year-over-year to $243.6 million, fueled by expanding prescriber adoption and longer treatment durations. Reflecting confidence in sustained commercial momentum, management raised full-year 2026 ARCALYST revenue guidance to $980–$995 million, up from $930–$945 million. On the pipeline front, Phase 2 data for KPL-387 demonstrated rapid pain and inflammation reduction, supporting the selection of a once-monthly 300 mg subcutaneous dose, and the pivotal Phase 3 PASTORALE trial is now enrolling. With $525.9 million in cash and no debt, the company is well-funded to execute on both commercial and clinical milestones.
At the time of this filing, KNSA was trading at $63.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $26.27 to $67.53. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.